InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（9 笔）
内部人交易记录
首席财务官已披露买入
1
已披露卖出
9
T+90 胜率
100%
T+90 平均收益
+18.1%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the complete record of transactions filed by Epperly Melissa B, 首席财务官. Officer active across 2 companies, notably Zentalis Pharmaceuticals, Inc.. In total, 32 reports have been published. Split: 1 buy · 9 sells. Total volume traded: €1.9m. History available since 3 May 2021. The latest transaction was disclosed on 17 July 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Epperly Melissa B,
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报32 总计
543 股0Common SharesSEC:0001140361-26-029192:0
670 股0Common SharesSEC:0001807359-26-000006:0
41,861 股@ US$28.6895.8% 占其流量Common SharesSEC:0001807359-26-000004:0
815 股0Common SharesSEC:0001140361-26-002085:0
1,056 股0Common SharesSEC:0001140361-25-038997:0
14,524 股0Common SharesSEC:0001140361-25-034929:0
1,609 股0Common SharesSEC:0001140361-25-026647:0
1,847 股0Common SharesSEC:0001140361-25-014802:0
1,672 股0Common SharesSEC:0001140361-25-002102:0
1,613 股0Common SharesSEC:0001140361-24-044060:0
4,245 股@ US$12.12100.0% 占其流量Common SharesSEC:0001140361-24-041233:0
16,406 股0Common SharesSEC:0001140361-24-040987:0
1,702 股0Common SharesSEC:0001140361-24-034279:0
1,146 股0Common SharesSEC:0001140361-24-022617:0
2,573 股@ US$11.440.9% 占其流量Common StockSEC:0001725160-24-000043:0
75,000 股0Common StockSEC:0001725160-24-000028:0
1,207 股0Common SharesSEC:0001140361-24-003552:0
1,226 股0Common SharesSEC:0001140361-23-048775:0
4,594 股@ US$19.42652.8% 占其流量Common StockSEC:0001725160-23-000179:0
17,825 股0Common SharesSEC:0001140361-23-044045:0
1,280 股0Common SharesSEC:0001140361-23-033547:0
2,624 股@ US$20.42441.7% 占其流量Common StockSEC:0001725160-23-000035:0
101,957 股0Common StockSEC:0001725160-23-000017:0
50,000 股0Common StockSEC:0001725160-22-000180:0
8,094 股@ US$48.74750.12% mcap12.7% 占其流量Common StockSEC:0001725160-22-000069:0
32 条申报中的 25 条
About Epperly Melissa B,
Melissa B. Epperly is Directeur Financier and is linked to Roivant Sciences Ltd. and Zentalis Pharmaceuticals, Inc. Across 31 filings in total, the 31 sampled filings run from 2021-05-05 to 2026-04-21, with 58913 EUR in buys and 1797499 EUR in sells; the most frequent transaction nature is Attribution.
